Merck’s pembrolizumab with berahyaluronidase alfa demonstrates noninferior PK compared to IV Keytruda in pivotal 3475A-D77 trial: Rahway, New Jersey Saturday, March 29, 2025, 10 ...
The global Analytical Standards Market, valued at US$1.44 billion in 2022, is forecasted to grow at a robust CAGR of 5.9%, reaching ...
The ongoing investigation by Wyden and his Democratic compatriots from the Finance Committee has pointed the finger at ...
Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...
US pharma major Merck & Co (NYSE: MRK) has shared the first results from a late-stage trial of a subcutaneous version of its ...
Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...
Merck (MRK) announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the subcutaneous administration of ...
Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...
The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...
The Philippine College of Occupational Medicine (PCOM) and healthcare company MSD in the Philippines have joined forces to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback